Almotriptan for menstrually related migraine

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 12, 2011, Pages 1933-1943

  Bussone, Gennaro ^a   Allais, Gianni ^b   Gabellari, Ilaria Castagnoli ^b   Benedetto, Chiara ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Almotriptan; Efficacy; Menstrually related migraine; Tolerability

Indexed keywords

ALMOTRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ASTHENIA; BONE PAIN; CLINICAL FEATURE; CONTROLLED STUDY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; LIPOPHILICITY; MENSTRUAL MIGRAINE; MIGRAINE WITHOUT AURA; NAUSEA; PARESTHESIA; REVIEW; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; ANALGESICS, NON-NARCOTIC; FEMALE; HUMANS; MENSTRUATION; MIGRAINE WITHOUT AURA; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TRYPTAMINES;

EID: 79960458864     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.594794     Document Type: Review

References (66)

1. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9 (Pubitemid 46184209)
2. MacGregor EA, Brandes J, Eikermann A, et al. Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) survey-Phase III. Curr Med Res Opin 2004;20:1143-50 (Pubitemid 38954477)
3. Wober C, Brannath W, Schmidt K, et al. PAMINA Study Group. Prospective analysis of factors relate to migraine attacks: the PAMINA study. Cephalalgia 2007;27:304-14 (Pubitemid 46434955)
4. Leone M, Vila C, McGown C. Influence of trigger factors on the efficacy of almotriptan as early intervention for the treatment of acute migraine in a primary care setting: the START study. Expert Rev Neurother 2010;10:1399-408
5. MacGregor EA. 'Menstrual' migraine: towards a definition. Cephalalgia 1996;16:11-21
6. Martin V, Lipton R. Epidemiology and biology of menstrual migraine. Headache 2008;48:S124-30
7. Loder E, Marcus DA. Migraine in women. Decker BC; Hamilton: 2004
8. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and non-menstrual attacks in women with menstrually related migraine referred to headache centers. Cephalalgia 2004;24:707-16 (Pubitemid 39209074)
9. MacGregor EA, Victor TW, Hu X, et al. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial. Headache 2010;50:528-38
10. Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000;55:1517-23
11. MacGregor A, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63:351-3 (Pubitemid 38971141)
12. Headache Classification Subcommittee of the International Headache Society (IHS). The international classification of headache disorders. 2nd edition. Cephalalgia 2004;24:S9-169
13. MacGregor A. Migraine in women. Martin Dunitz Ltd; London: 1999
14. Somerville BW. Estrogen-withdrawal migraine: I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. Neurology 1975;25:239-44
15. MacGregor EA, Frith A, Ellis J, et al. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 2006;67:2154-8 (Pubitemid 46035468)
16. Loder EW. Menstrual migraine: pathophysiology, diagnosis, and impact. Headache 2006;46:S49-54
17. Nattero G, Allais G, De Lorenzo C, et al. Menstrual migraine: new biochemical and psychological aspects. Headache 1988;28:103-7 (Pubitemid 20344995)
18. Nattero G, Allais G, De Lorenzo C, et al. Relevance of prostaglandins in true menstrual migraine. Headache 1989;29:233-8 (Pubitemid 20346772)
19. Fioroni L, Martignoni A, Facchinetti F. Changes of neuroendocrine axes in patients with menstrual migraine. Cephalalgia 1995;15:297-300
20. Fioroni L, D'Andrea G, Alecci M, et al. Platelet serotonin pathway in menstrual migraine. Cephalalgia 1996;16:427-30 (Pubitemid 26338474)
21. Benedetto C, Allais G, Ciochetto D, et al. Pathophysiological aspects of menstrual migraine. Cephalalgia 1997;17:S32-4
22. Silberstein SD. The role of sex hormones in headache. Neurology 1992;42:37-42
23. MacGregor A. Menstruation, sex hormones and migraine. Neurol Clin 1997;15:125-41
24. Couturier EG, Bomhof MA, Neven AK, et al. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003;23:302-8 (Pubitemid 36577949)
25. Martin VT, Wernke S, Mandell K, et al. Defining the relationship between ovarian hormones and migraine headache. Headache 2005;45:1190-201 (Pubitemid 350004908)
26. Dowson AJ, Kilminster SG, Salt R, et al. Disability associated with headaches occurring inside and outside the menstrual period in those with migraine: a general practice study. Headache 2005;45:274-82 (Pubitemid 40530191)
27. Granella F, Sances G, Messa G, et al. Treatment of menstrual migraine. Cephalalgia 1997;17:S35-8
28. MacGregor A. Migraine associated with menstruation. Funct Neurol 2000;15:S143-53
29. Visser WH, Jaspers NM, de Vriend RH, et al. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996;16:264-9 (Pubitemid 26189253)
30. Silberstein SD, Massiou H, McCarroll KA, et al. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002;42:917-23 (Pubitemid 35285385)
31. Diamond ML, Cady RK, Mao L, et al. Characteristic of migraine attacks and response to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines. Headache 2008;48:248-58 (Pubitemid 351178257)
32. Pinkerman B, Holroyd K. Menstrual and nonmenstrual migraines differ in women with menstrually-related migraine. Cephalalgia 2010;30:1187-94
33. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668-75 (Pubitemid 33124324)
34. Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58 (Pubitemid 36609333)
35. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Obstet Gynecol 1993;82:769-72 (Pubitemid 23312185)
36. Facchinetti F, Bonellie G, Kangasniemi P, et al. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group. Obstet Gynecol 1995;86:911-16 (Pubitemid 27331483)
37. Gross MLP, Barrie M, Bates D, et al. The efficacy of oral sumatriptan in menstrual migraine: a prospective study. Cephalalgia 1995;15:S227
38. Nett R, Landy S, Shackelford S, et al. Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003;102:835-42 (Pubitemid 37206421)
39. Landy S, Savani N, Shackelford SJ, et al. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract 2004;58:913-19 (Pubitemid 39642611)
40. Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain 2005;6:81-7 (Pubitemid 40667559)
41. Mannix LK, Martin VT, Cady RK, et al. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 2009;114:106-13
42. Facchinetti F, Allais G, Nappi RE, et al. Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecol Endocrinol 2010;26:773-9
43. Silberstein SD, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 2000;96:237-42 (Pubitemid 30447346)
44. Massiou H, Silberstein SD, McCarrol KA, et al. Efficacy of rizatriptan in menstrual migraine: freedom from pain and associated symptoms at 2-h and 24-h sustained pain free status [abstract]. Cephalalgia 2000;20:343-4
45. Silberstein SD, Massiou H, McCarroll KA, et al. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002;42:917-23 (Pubitemid 35285385)
46. Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia 2007;27:414-21 (Pubitemid 46632603)
47. Bigal M, Sheftell F, Tepper S, et al. A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. Headache 2008;48:1286-93
48. Nett R, Mannix LK, Mueller L, et al. Rizatriptan efficacy in ICHD-II pure menstrual migraine and menstrually related migraine. Headache 2008;48:1194-201
49. Martin V, Cady R, Mauskop A, et al. Efficacy of rizatriptan for menstrual migraine in an early intervention model: a prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache 2008;48:226-35 (Pubitemid 351178285)
50. Silberstein S. Zolmitriptan is effective in the treatment of menstrually associated migraine attacks. Cephalalgia 2001;21:420
51. Loder E, Silberstein SD, Abu-Shakra S, et al. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004;44:120-30 (Pubitemid 38233753)
52. Tuchman M, Hee A, Emeribe U, et al. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs 2006;20:1019-26 (Pubitemid 44912709)
53. Allais G, Acuto G, Cabarrocas X, et al. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine. Neurol Sci 2006;27:S193-7 (Pubitemid 44390141)
54. Allais G, Bussone G, D'Andrea G, et al. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2011;31:144-51
55. Allais G, Acuto G, Benedetto C, et al. Evolution of migraine-associated symptoms in menstrually related migraine following symptomatic treatment with almotriptan. Neurol Sci 2010;31:S115-19
56. Bou J, Domenech T, Puig J, et al. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000;410:33-41 (Pubitemid 32008128)
57. Bou J, Gras J, Cortijo J, et al. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21:804-12 (Pubitemid 34621525)
58. Hoskin KL, Lambert GA, Donaldson C, et al. The 5-hydroxytry ptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res 2004;998:91-9 (Pubitemid 38081286)
59. Gras J, Bou J, Llenas J, et al. Functional profile of almotriptan in animal models predictive of antimigraine activity. Eur J Pharmacol 2000;410:43-51 (Pubitemid 32008129)
60. Salva M, Jansat JM, Martinez-Tobed A, et al. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos 2003;31:404-11 (Pubitemid 36382888)
61. Buzzi MG. Pathways to the best fit of triptans for migraine patients. Cephalalgia 2008;28:S21-7
62. Pascual J, Vila C, McGown CC. Almotriptan: a review of 10 years' clinical experience. Expert Rev Neurother 2010;10:1505-17
63. Goadsby PJ, Massiou H, Cabarrocas X, et al. Randomized double-blind trial comparing the efficacy and tolerability of almotriptan and zolmitriptan in the acute treatment of migraine. Eur J Neurol 2005;12:S195
64. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT® Early Migraine Intervention Study). Headache 2007;47:189-98
65. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001;41:449-55 (Pubitemid 32466392)
66. Freitag FG, Finlayson G, Rapoport AM, et al. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS). Headache 2007;47:519-30 (Pubitemid 46625261)